依达拉奉注射液联合阿司匹林肠溶片治疗急性缺血性脑卒中的临床研究  

Clinical trial of edaravone injection combined with aspirin enteric-coated tablets in the treatment of acute ischemic stroke

作　　者：刘晓霞[1] 朱蓓蕾[2] 杨迎民[1] LIU Xiao - xia,ZHU Bei - lei2, YANG Ying - min1(1.Department of Rehabilitation, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang Province, China; 2. Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, Chin)

机构地区：[1]温州市中医院康复科,浙江温州325000 [2]温州医科大学附属第一医院神经内科,浙江温州325000

出　　处：《中国临床药理学杂志》2018年第7期753-755,共3页The Chinese Journal of Clinical Pharmacology

基　　金：浙江省医药卫生计划基金资助项目(2011ZHA011;2011KYB057)

摘　　要：目的观察依达拉奉注射液联合阿司匹林肠溶片治疗急性缺血性脑卒中的临床疗效及安全性。方法将114例急性缺血性脑卒中患者随机分为对照组57例和试验组57例。对照组予以阿司匹林每次100 mg,qd,口服;试验组在对照组治疗的基础上,予以依达拉奉每次30 mg,bid,静脉滴注,30 min内滴完。2组患者均治疗2周。比较2组患者的临床疗效、神经功能缺损程度(NIHSS)评分、血浆脂蛋白相关性磷脂酶A2(Lp-PLA2)、花生四烯酸(AA)和腺苷二磷酸(ADP)途径诱导的血小板抑制率,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为91.23%(52例/57例)和68.42%(39例/57例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的NIHSS评分分别为(5.53±1.24)和(10.02±1.26)分,Lp-PLA2分别为(18.00±4.68)和(31.84±5.62)μg·L^(-1),AA途径诱导的血小板抑制率分别为(94.50±3.16)%和(70.65±3.60)%,ADP途径诱导的血小板抑制率分别为(56.49±0.36)%和(45.21±0.87)%,差异均有统计学意义(均P<0.05)。试验组发生的药物不良反应以头痛为主,对照组发生的药物不良反应以药物过敏反应、头痛和耳鸣为主。试验组和对照组的总药物不良反应率分别为1.75%和10.53%,差异有统计学意义(P<0.05)。结论依达拉奉注射液联合阿司匹林肠溶片治疗急性缺血性脑卒中的临床疗效确切,其能显著降低血浆Lp-PLA2水平和NIHSS评分,提高AA和ADP途径诱导的血小板抑制率,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of edaravone injection combined with aspirin enteric -coated tablets in the treatment of acute ischemic stroke. Methods A total of 114 patients with acute ischemic stroke were divided into control group and treatment group with 57 cases per group. Control group was given aspirin 100 mg per time, qd, orally. Treatment group was given edaravone 30 mg per time, bid, intravenous drip within 30 min, on the basis of control group. Two groups were treated for 2 weeks. The clinical efficacy, national insti- tutes of health stroke scale （NIHSS） scores, serum lipoprotein - asso- ciated phospholipase A2 （ Lp - PLA2 ）, arachidonic acid （ AA ） and adenosine diphosphate （ADP） induced inhibition rates of platelet aggre- gation, and adverse drug reactions were compared between two groups.Results After treatment, the total effective rates of treatment and control groups were 91.23 % （52 cases / 57 cases） and 68.42% （39 cases / 57 cases） with significant difference （P 〈0. 05）. After treatment, the main indexes in treat- ment and control groups were compared： the NIHSS scores were （5.53 ± 1.24） and （ 10. 02 ± 1.26） points, Lp - PLA2 were （ 18.00 ± 4.68 ） and （31.84 ± 5.62） μg·L-1, The inhibition rates of platelet aggregation induced byAA were （94.50 ±3.16）% and （70.65 ±3.60）%, which induced by ADP were （56.49 ±0.36）% and （45.21 ± 0. 87 ）%, the differences were statistically significant （all P 〈 0. 05 ）. The adverse drug reactions in treat- ment group were headache, which in control group were drug allergies, headaches and tinnitus. The total incidences of adverse drug reactions in treatment and control groups were 1.75% and 10. 53% without significant difference （P 〉 0. 05 ）. Conclusion Edaravone injection combined with aspirin enteric -coated tablets has a definitive clinical efficacy in the treatment of acute ischemic stroke, which can significantly reduce the levels of Lp - PLA2, improve the

关 键 词：依达拉奉注射液 阿司匹林肠溶片 急性缺血性脑卒中 安全性 

分 类 号：R972[医药卫生—药品]